Project Grant R43AR083730
Award Date
9/20/23
Completion Date
3/31/24
Dollars Obligated
$295K
Similar Awards
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $628,968 project grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to define and treat genetic abnormalities in psoriasis/atopic dermatitis-overlap dermatoses. The project aims to use high-resolution, quantitative biomarkers to understand the etiology of these "PSO-AD" rashes and determine if they...
This Project Grant award of $664,933, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to define the cellular and molecular pathways underlying interleukin-17A (IL-17A)-induced pathologies in psoriatic arthritis. The awardee, Beth Israel Deaconess Medical Center, Inc. (BIDMC), will use a novel animal model of IL-17A gene transfer to investigate...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. This grant will fund the development and characterization of recombinant, cell-penetrating botulinum protease variants that can inhibit the release of neuropeptides and cytokines in neurons and immune cells, respectively. The goal is to create a new topical therapeutic...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This Project Grant award of $239,488 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to characterize the inflammatory pathologies underlying axial psoriatic arthritis (axPsA) using total-body positron emission tomography/computed tomography (TB-PET/CT) imaging. The research aims to provide novel, objective, and quantifiable TB-PET/CT imaging biomarkers...
This Project Grant award of $673,729.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to define the impact of dietary conjugated linoleic acid (CLA) on the formation of nitro-fatty acids (NO2-FAs) in skin tissues and establish their protective effects on psoriasis. The University of Pittsburgh will pursue three specific aims: 1) Defining the...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,450 to Lybra Bio Inc. aims to advance the development of a hydrogel-based microneedle patch for managing autoimmune skin diseases such as alopecia areata, vitiligo, and psoriasis. The project seeks to modulate the drug release profile of the microneedle patch and determine the minimum wear time required for therapeutic efficacy. This work is intended to prepare the...